Kainova Therapeutics Reports Positive Phase I Results for Oral EP4 Receptor Antagonist DT-9081 in Advanced Solid Tumors
核心洞察
Kainova Therapeutics (搜索) announced positive Phase I EPRAD study results for DT-9081, an oral EP4 receptor (搜索) antagonist, demonstrating favorable safety profile and sustained target engagement across all tested doses in patients with advanced solid tumors (搜索).
The study conducted across four sites in France and Belgium met all primary objectives with no dose-limiting toxicities reported, validating DT-9081's clinical tolerability and mechanism of action.
Early signs of anti-tumor activity were observed, supporting EP4 receptor (搜索) antagonism as a strategy to overcome PGE2-driven immune suppression and potentially improve responses to immune checkpoint inhibitors.
Kainova Therapeutics (搜索) has announced positive topline results from its Phase I EPRAD study evaluating DT-9081, a proprietary oral small molecule EP4 receptor (搜索) antagonist in patients with advanced, recurrent, and metastatic solid tumors. The study, conducted across four sites in France and Belgium, met all primary objectives and demonstrated a favorable safety profile with early signs of anti-tumor activity.
Study Design and Primary Outcomes
The Phase I EPRAD study evaluated DT-9081's safety, pharmacokinetic, and pharmacodynamic characteristics in patients with advanced solid tumors (搜索). Results showed dose-proportional exposure and sustained EP4 receptor (搜索) engagement across all tested doses. Notably, no dose-limiting toxicities were reported at any dose level, confirming DT-9081's clinical tolerability and validating its mechanism of action.
Professor Jean-Pascal Machiels, Principal Investigator of the EPRAD study, commented: "The results of the study not only validate EP4 receptor (搜索) antagonism as a powerful mechanism to counteract PGE2-driven immune suppression, but also demonstrate the clinical potential of DT-9081 across a range of tumor types. Since chemotherapy and other standard treatments often trigger PGE2 production by cancer cells, restoring competence through selective EP4 inhibition offers a rational and versatile strategy to overcome resistance."
Clinical Profile and Mechanism of Action
Dr. Jean-Marie Cuillerot, Chief Medical Officer of Kainova Therapeutics (搜索), emphasized the study's comprehensive dataset: "The Phase I EPRAD study generated a clear and coherent dataset that precisely characterizes DT-9081's clinical profile. Across all dose levels, we observed consistent safety findings together with robust PK/PD readouts. The high-quality clinical and translational data obtained in this study are essential for understanding how EP4 antagonism behaves in patients with advanced solid tumors (搜索) in a clinical setting."
DT-9081 is designed as a best-in-class oral EP4 receptor (搜索) antagonist that aims to reverse Prostaglandin E2 (PGE2)-mediated immunosuppression within the tumor microenvironment. Preclinical studies have demonstrated significant anti-tumor effects in triple-negative breast cancer (搜索), sarcoma (搜索), and colorectal cancer (搜索) models, both as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors.
Therapeutic Strategy and Future Implications
The Phase I findings support DT-9081's potential to improve responses to immune checkpoint inhibitors by targeting PGE2-driven immune suppression. PGE2, produced by COX-2 (搜索) positive tumors, promotes tumor progression, and by selectively inhibiting the EP4 receptor (搜索), DT-9081 aims to restore an immunocompetent environment and support immune reactivation.
Sean A. MacDonald, Chief Executive Officer of Kainova Therapeutics (搜索), stated: "The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative approach to targeting the EP4 receptor (搜索) to overcome tumor-induced immunosuppression. The favorable safety and early efficacy signals observed with DT-9081 provide meaningful insight into EP4 biology and its role in immuno-oncology."
GPCR-Targeting Approach
The results reinforce Kainova Therapeutics (搜索)' focus on G protein-coupled receptors (GPCRs) as therapeutic targets in immuno-oncology. While GPCRs represent the most validated drug target family with 30-35% of all marketed drugs acting on them, existing drugs target only 10% of the total potential GPCR targets. The company's approach recognizes the substantial untapped potential of GPCRs in immuno-oncology and inflammatory diseases.
DT-9081 is supported by a comprehensive biomarker strategy that enables precise monitoring of EP4 receptor (搜索) engagement during treatment, helping inform clinical positioning and ensure efficient clinical trial strategy. Full Phase I study details are available on clinicaltrials.gov under identifier NCT05582850.